Company Encyclopedia
View More
name
OpGen
OPGN.US
OpGen, Inc., a precision medicine company, develops and commercializes molecular microbiology solutions for life threatening infectious diseases in the United States and internationally. The company’s products include Unyvero application cartridges, Unyvero systems, Acuitas AMR Gene Panel test products, and SARS CoV-2 test kits. It also provides laboratory services; collaboration services, including funded software arrangements; and license arrangements services. In addition, the company offers listing sponsorship and consultancy services.
1.946 T
OPGN.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
A
BiotechnologyIndustry
Industry Ranking5/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE102.11%A
    • Profit Margin76.04%A
    • Gross Margin0.00%E
  • Growth ScoreA
    • Revenue YoY610.97%A
    • Net Profit YoY167.66%A
    • Total Assets YoY131.07%A
    • Net Assets YoY240.16%A
  • Cash ScoreB
    • Cash Flow Margin134.12%C
    • OCF YoY610.97%A
  • Operating ScoreA
    • Turnover0.99A
  • Debt ScoreA
    • Gearing Ratio19.63%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    OpGen (OTC:OPGN) Stock Crosses Above Fifty Day Moving Average - What's Next?

    OpGen's stock price surged above its 50-day moving average, trading as high as $5.04, marking an 80% increase. Despite this rise, analysts suggest other stocks may be better investments, as OpGen holds a 'Hold' rating. The company specializes in molecular microbiology solutions.

    Market Beat·
    US
    OPGN
    +9.77%
    Market Beat·
    US
    OPGN
    +9.77%

    OpGen | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    OPGN
    +9.77%
    LB filings·
    US
    OPGN
    +9.77%

    OpGen Delays Quarterly Financial Filing

    OpGen Inc. announced a delay in filing its Quarterly Report on Form 10-Q for the period ended September 30, 2025, due to limited resources and personnel. The company expects significant changes in its operations compared to last year and plans to file within the extension period. This information was disclosed via EDGAR by the U.S. SEC.

    Reuters·
    US
    OPGN
    +9.77%
    Reuters·
    US
    OPGN
    +9.77%

    OpGen | 10-Q: FY2025 Q2 Revenue: USD 4 M

    LB filings·
    US
    OPGN
    +9.77%
    LB filings·
    US
    OPGN
    +9.77%

    OpGen | 10-Q: FY2025 Q1 Revenue: USD 0

    LB filings·
    US
    OPGN
    +9.77%
    LB filings·
    US
    OPGN
    +9.77%
    © 2025 Longbridge｜Disclaimer